The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk

Transplant International

Volumn 24, Issue 5, 2011, Pages 469-476

  Nannya, Yasuhito ^a   Kataoka, Keisuke ^a   Hangaishi, Akira ^a   Imai, Yoichi ^a   Takahashi, Tsuyoshi ^a   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Disease risk; Hematopoietic stem cell transplantation; Sex mismatch

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DONOR SELECTION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WHOLE BODY RADIATION; Y CHROMOSOME;

ADOLESCENT; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; CHROMOSOMES, HUMAN, Y; FEMALE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK; SEX FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79953772864     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01229.x     Document Type: Article

References (18)

1. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043.
2. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 758.
3. Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol 2007; 20: 219.
4. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027.
5. Meadows L, Wang W, den Haan JM, et al. The HLAA* 0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6: 273.
6. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000; 164: 2807.
7. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 2000; 95: 1100.
8. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715.
9. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus- leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103: 347.
10. Gallardo D, Perez-Garcia A, de la Camara R, et al. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source. Leukemia 2006; 20: 1461.
11. Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003; 102: 1541.
12. Yoshimi A, Nannya Y, Sakata-Yanagimoto M, et al. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation. Int J Hematol 2008; 83: 635.
13. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576.
14. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989; 74: 2252.
15. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
16. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397.
17. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674.
18. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838.